RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shenzhen’s China Medical System acquired China rights to seven generic drugs from India’s Sun Pharma. The seven drugs were not identified, but Sun Pharma said they have China market revenues of $1 billion annually. Two months ago, CMS in-licensed two other Sun Pharma products, a treatment for dry eye and a biologic treatment for psoriasis. Sun Pharma is one of several Indian drug companies that are now bringing their products to China, usually by forming relationships with China companies. The financial details of the agreement were not disclosed. Source: China Biotoday